EPIQ Capital Group’s Quince Therapeutics QNCX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $1.54M | Sell |
824,782
-1,160
| -0.1% | -$2.17K | 0.4% | 30 |
|
|
2024
Q3 | $641K | Sell |
825,942
-26,419
| -3% | -$20.5K | 0.18% | 40 |
|
|
2024
Q2 | $639K | Buy |
852,361
+6,588
| +0.8% | +$4.94K | 0.23% | 37 |
|
|
2024
Q1 | $897K | Sell |
845,773
-24,360
| -3% | -$25.8K | 0.36% | 26 |
|
|
2023
Q4 | $914K | Sell |
870,133
-56,367
| -6% | -$59.2K | 0.42% | 19 |
|
|
2023
Q3 | $1.04M | Sell |
926,500
-6,680
| -0.7% | -$7.48K | 0.54% | 18 |
|
|
2023
Q2 | $1.4M | Sell |
933,180
-25,289
| -3% | -$38.1K | 0.71% | 16 |
|
|
2023
Q1 | $1.5M | Sell |
958,469
-97,722
| -9% | -$152K | 0.75% | 15 |
|
|
2022
Q4 | $673K | Sell |
1,056,191
-1,000,478
| -49% | -$638K | 0.37% | 23 |
|
|
2022
Q3 | $2.74M | Sell |
2,056,669
-1,218,879
| -37% | -$1.62M | 1.35% | 13 |
|
|
2022
Q2 | $7.27M | Sell |
3,275,548
-803,913
| -20% | -$1.78M | 2.85% | 9 |
|
|
2022
Q1 | $20M | Sell |
4,079,461
-189,648
| -4% | -$930K | 5.47% | 8 |
|
|
2021
Q4 | $53.9M | Buy |
4,269,109
+315,514
| +8% | +$3.98M | 9.57% | 3 |
|
|
2021
Q3 | $362M | Buy |
3,953,595
+188,090
| +5% | +$17.2M | 37.45% | 1 |
|
|
2021
Q2 | $200M | Buy |
3,765,505
+109,706
| +3% | +$5.81M | 20.85% | 2 |
|
|
2021
Q1 | $132M | Buy |
3,655,799
+148,717
| +4% | +$5.36M | 14.71% | 3 |
|
|
2020
Q4 | $97.4M | Buy |
3,507,082
+92,210
| +3% | +$2.56M | 15.42% | 2 |
|
|
2020
Q3 | $171M | Buy |
3,414,872
+72,117
| +2% | +$3.61M | 24.43% | 2 |
|
|
2020
Q2 | $155M | Buy |
3,342,755
+148,258
| +5% | +$6.86M | 26.08% | 2 |
|
|
2020
Q1 | $146M | Buy |
3,194,497
+51,103
| +2% | +$2.33M | 43.1% | 1 |
|
|
2019
Q4 | $176M | Buy |
+3,143,394
| New | +$176M | 43.18% | 1 |
|